Jade Biosciences (JBIO) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Pipeline and development milestones

• Three autoimmune programs: JADE-101, an anti-APRIL antibody; JADE-201, an afucosylated anti-BAFF-R antibody; and JADE-301, an anti-interferon beta antibody.

• JADE-101 Phase II began in May 2026, with data expected in Q2 2027; a global registrational Phase III is planned to start in Q4 2026.

• JADE-201 Phase I in RA began in May 2026, with data expected in 2027; JADE-301 healthy-volunteer Phase I is planned to start in Q4 2026, with data expected in 2H 2027.

JADE-101 and IgAN opportunity

• Phase I results support confidence in Q12-week dosing; the YTE Fc modification extends half-life, and the molecule is described as a femtomolar APRIL binder.

• Management views sibeprenlimab as on track for ~$400 million in sales in 2026, versus prior consensus peak sales below $100 million; it expects APRIL-targeting therapies to become standard of care.

• KDIGO targets cited were proteinuria below 0.5 g/day, preferably below 0.3 g/day; selective APRIL inhibition and less frequent dosing were presented as potential differentiators.

• Phase III design: 2:1 randomization, double-blind for one year, then 48 weeks open-label with all participants receiving active drug; exploratory cohorts include eGFR 20–30 and proteinuria 0.5–0.75.

• Q2 2027 Phase II data are expected to provide a meaningful dataset, with at least six months of follow-up targeted; planned analyses include UPCR and Gd-IgA1 reductions.

JADE-201 and JADE-301

• JADE-201 is designed for enhanced ADCC and deep, rapid B-cell depletion; BAFF-R blockade may also limit compensatory B-cell repopulation associated with BAFF-ligand inhibition.

• JADE-201 Phase I in RA uses patients without access to therapies such as rituximab, enabling assessment of B-cell depletion and receptor occupancy; indication prioritization is planned after 2027 data.

• Nonclinical studies showed JADE-201 doubled ianalumab’s 10-day human half-life in NHPs, potentially supporting longer or broader receptor occupancy.

• JADE-301 is being developed initially for dermatomyositis; subcutaneous dosing is planned from the healthy-volunteer study, with protein engineering intended to support monthly or less frequent dosing.

• Dazukibart Phase II results cited included a ~16-point CDASI reduction; JADE-301 aims to reproduce clinical activity with subcutaneous administration.